Climb Bio, Inc.
$8.97
▼
-5.61%
2026-04-21 06:05:01
climbbio.com
NGM: CLYM
Explore Climb Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$437.55 M
Current Price
$8.97
52W High / Low
$9.4 / $1.13
Stock P/E
—
Book Value
$3.36
Dividend Yield
—
ROCE
-42.23%
ROE
-32.15%
Face Value
—
EPS
$-0.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
-0.2
Debt / Equity
0.34
Current Ratio
15.16
Quick Ratio
15.16
Forward P/E
-5.76
Price / Sales
—
Enterprise Value
$301.19 M
EV / EBITDA
-4.44
EV / Revenue
—
Rating
Strong Buy
Target Price
$15.36
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 2. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 3. | TuHURA Biosciences, Inc. | $2.83 | — | $179.93 M | 0% | -120.19% | -1.69% | $4.44 / $0.41 | $0.35 |
| 4. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 5. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
| 6. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
| 7. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -19.3 M | -14.89 M | -10.68 M | -23.02 M | -10.91 M | — |
| Net Profit | -17.52 M | -12.89 M | -8.67 M | -20.78 M | -8.42 M | — |
| EPS in Rs | -0.37 | -0.27 | -0.18 | -0.44 | -0.18 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -67.88 M | -30.36 M | -40.27 M | -45.13 M |
| Net Profit | -59.85 M | -73.9 M | -35.12 M | -45.24 M |
| EPS in Rs | -1.25 | -1.55 | -0.74 | -0.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 167.74 M | 217.19 M | 110.47 M | 134.99 M |
| Total Liabilities | 7.27 M | 5.31 M | 2.87 M | 6.28 M |
| Equity | 160.47 M | 211.88 M | 107.6 M | 128.72 M |
| Current Assets | 105.85 M | 154.87 M | 110.25 M | 134.39 M |
| Current Liabilities | 6.98 M | 4.93 M | 2.83 M | 6.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -54.36 M | -15.56 M | -20.6 M | -37.37 M |
| Investing CF | 2.83 M | -121.09 M | 68.98 M | 34.44 M |
| Financing CF | -0.02 M | 130.73 M | 0.84 M | 0 M |
| Free CF | -54.54 M | -15.56 M | -20.6 M | -37.37 M |
| Capex | -0.19 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -110.42% | 22.38% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.